Coya Therapeutics financials
$5.03+1.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | $0.00 |
| Gross profit | $7.9M | $3.6M | $6.0M | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$22.6M | -$17.2M | -$7.9M | -$9.8M |
| Net income | -$21.2M | -$14.9M | -$8.0M | -$12.2M |
| Net margin | −267.1% | −418.7% | −133.1% | — |
| Diluted EPS | $-1.27 | $-0.98 | $-0.79 | $-4.73 |
| EBITDA | -$22.5M | -$17.2M | -$7.9M | -$9.8M |
| Operating cash flow | -$10.7M | -$10.3M | -$11.2M | -$7.2M |
| Free cash flow | -$10.7M | -$10.3M | -$11.2M | -$7.2M |
| Diluted shares | 16.7M | 15.2M | 10.2M | 2.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $46.8M | $38.3M | $32.6M | $5.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $13.0M |
| Total assets | $50.0M | $44.3M | $41.3M | $8.4M |
| Total liabilities | $6.9M | $4.8M | $5.6M | $16.8M |
| Shareholders' equity | $43.0M | $39.6M | $35.6M | -$8.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology